One of the paintings from Gilead's latest campaign making AI art to help MBC patients be 'seen and heard.'
February 3, 2023 02:07 PM EST
Pharma
Marketing

Gilead com­bines ar­ti­fi­cial in­tel­li­gence and art to draw at­ten­tion and hope to MBC

Beth Snyder Bulik

Senior Editor

What if you could “see” the emo­tions and feel­ings of peo­ple liv­ing with metasta­t­ic breast can­cer? That’s what Gilead Sci­ences’ agency VM­LY&R Health did last …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times